Anti-Neurodegenerative Disease Compound Library

Catalog No. L2620

Neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), spinal muscular atrophy (SMA), and amyotrophic lateral sclerosis (ALS), are incurable and debilitating conditions characterized by progressive degeneration of specific neurons within the brains of affected individuals. Neurodegenerative diseases have become an enormous economic burden that is projected to grow significantly over the next few decades in the absence of any new therapeutic interventions. Drugs for the central nervous system, including neurodegenerative diseases, that entered clinical development, have a considerably lower probability of reaching the marketplace (7%) than the industry average across other therapeutic areas (15%), and require a longer time for development and regulatory approval (average of 12.6 years) compared with most other diseases (e.g., 6.3 years for cardiovascular and 7.5 years for gastrointestinal indications). In this compound library, TargetMol collects 2154 compounds related to neurodegenerative diseases having therapeutic effect or acting on neurodegenerative disease-related targets.

All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.